Compare Amgen, Inc. (AMGN) vs GE Vernova Inc (GEV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs GE Vernova Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while GE Vernova Inc trades at $1,081 (market cap $293.33B). The key difference: GE Vernova Inc is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | GEV | |
|---|---|---|
Market Cap | $196.12B | $293.33B |
Sector | Health | Technology |
52-Week High | $388.16 | $1.17K |
52-Week Low | $271.18 | $539.16 |
Enterprise Value | $241.41B | $285.96B |
Dividend Yield | 2.77% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GE Vernova (GEV) trades at $1,091.57, up 1.52% with strong analyst support (75% buy ratings) and a consensus price target of $1,230. The stock shows bullish technical momentum with recent earnings beats and robust profitability metrics including 23.81% net income margin and 83.23% ROE. Recent news highlights the company's strategic positioning in AI power infrastructure and nuclear energy expansion.
Outlook remains positive with projected revenue growth to $39.4B and net profit doubling to $9.4B in 2026. Key risks include high valuation multiples (P/E 31.9, EV/EBITDA 113.7) and execution challenges in scaling nuclear operations. The stock offers exposure to AI-driven power demand but faces volatility from energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
